2018 American Transplant Congress
Contemporary Desensitization with Low Dose Rituximab Ensures Kidney Transplant Outcome beyond ABO Blood Type Incompatibility:A Comparison between past Regimens in Single Institute
Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
INTRODUCTION: An ABO incompatible kidney transplant (ABOiKT) requires desensitization (DS). The ways of DS have been changed chronologically and the outcome could have been subsequently…2018 American Transplant Congress
Long-Term Success of Treatment for Cardiac Transplant AMR May Depend Upon Suppressing Class II Donor Specific Antibodies
Antibody mediated rejection (AMR) in cardiac transplant (tspt) patients (pts) is primarily mediated by donor specific antibodies (DSAs) and associated with reduced long-term graft survival.…2018 American Transplant Congress
Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients
Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…2018 American Transplant Congress
Recurrence of Focal Segmental Glomerulosclerosis (FSGS) and Response to Prolonged Plasmapheresis Therapy: A Single Center Pediatric Experience
FSGS is the most common glomerular cause of ESKD in pediatric patients. The risk of recurrence after kidney transplant (KT) is 30-60%, and half of…2018 American Transplant Congress
Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients
Purpose: Evaluate the efficacy and safety of acute antibody mediated rejection (AMR) treatment modalities in pediatric kidney transplant recipients (KTR).Methods: A single-center retrospective chart review…2018 American Transplant Congress
Preemptive Plasma Therapy and Eculizumab (ECU) Rescue for Atypical Hemolytic Uremic Syndrome (aHUS) Relapse Following Kidney Transplantation (KTX)
Introduction: KTX in aHUS patients is associated with a high rate of relapse and graft loss. Here, we report on seven aHUS cases with end-stage…2018 American Transplant Congress
Treatment Outcomes of FSGS Recurrence
Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…2017 American Transplant Congress
Successful Launch of an ABO-Incompatible Kidney Transplantation Program to Overcome the Shortage of Compatible Living Donors: Experience at a Single Center.
Introduction:ABO-incompatible (ABOi) kidney transplantation (KT) is being increasingly performed to overcome donor shortages. However, debate persists regarding the post-transplant outcomes of ABOi KT versus that…2017 American Transplant Congress
Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.
Background. Plasmapheresis for antibody removal and rituximab for antibody production suppression are performed for desensitization against ABO-incompatible kidney transplantation. We evaluated clinical outcome for optimizing…2017 American Transplant Congress
The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.
Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented.Aim: To compare…
American Transplant Congress abstracts